Thymoglobulin
Thymoglobulin is a pharmaceutical drug with 72 clinical trials. Currently 7 active trials ongoing. Historical success rate of 76.4%.
Success Metrics
Based on 42 completed trials
Phase Distribution
Phase Distribution
10
Early Stage
36
Mid Stage
20
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
73.7%
42 of 57 finished
26.3%
15 ended early
7
trials recruiting
72
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Methods of T Cell Depletion Trial (MoTD)
Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor
Allo HSCT for High Risk Hemoglobinopathies
The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
Clinical Trials (72)
Methods of T Cell Depletion Trial (MoTD)
Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor
Allo HSCT for High Risk Hemoglobinopathies
The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
Autologous Stem Cell Transplant for Crohn's Disease
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)
Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study
Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
Non-Myeloablative Conditioning and Bone Marrow Transplantation
Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant
Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation
Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols
Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation
Selective CD28 Blockade in Renal Transplant Recipients
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 72